4- Thursday Pharmacotherapy News – 20th May

1 – Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients

• COVID-19 vaccination is recommended for multiple sclerosis patients.
• Disease-modifying therapies can influence the safety and efficacy of COVID-19 vaccines. RNA, DNA, protein, and inactivated vaccines are likely safe for multiple sclerosis patients.
• Live-attenuated vaccines should be avoided whenever possible in treated patients. Interferon-beta, glatiramer acetate, teriflunomide, fumarates, and natalizumab are not expected to impact vaccine efficacy, while cell-depleting agents (ocrelizumab, rituximab, ofatumumab, alemtuzumab, and cladribine) and sphingosine-1-phosphate modulators will likely attenuate vaccine responses.

Source: ScienceDirect

2 – A mini-review on Sofosbuvir and Daclatasvir treatment in COVID-19

• Sofosbovir and daclatasvir have been used successfully since 2013 for hepatitis C virus treatment .
• It has been shown by different studies that sofosbovir can inhibit RNA polymerase of other positive-strand RNA viruses including Flaviviridae and Togaviridae.
• Homology between HCV RNA polymerase and SARS-CoV-2 has also been established.
• The efficacy of sofosbuvir and daclatsvir as potential choices in treating patients with COVID-19 and their recovery can be hypothesized.

Source: ScienceDirect

3 – Real-World Effectiveness of Mepolizumab in Severe Eosinophilic Asthma: A Systematic Review and Meta-analysis

• Mepolizumab is a human monoclonal antibody against interleukin 5 (IL-5) used to treat severe eosinophilic asthma.
• Several studies have evaluated the effectiveness of mepolizumab in the real world.
• They conducted a systematic review and meta-analysis in the context of heterogeneity among patients, clinicians, and treatment regimens to study the effectiveness of mepolizumab in the real world.
• Mepolizumab is associated with improvements in several clinically meaningful real-world outcomes.

Source: Clinical Therapeutics

4- Effect of Statin Therapy on the Carboxypeptidase U (CPU, TAFIa, CPB2) System in Patients With Hyperlipidemia: A Proof-of-Concept Observational Study

• Statins are commonly used in patients with hypercholesterolemia to lower their cholesterol levels and to reduce their cardiovascular risk.
• There is also considerable evidence that statins possess a range of cholesterol-independent effects, including profibrinolytic properties.
• This pilot study aimed to explore the influence of statins on procarboxypeptidase U (proCPU) biology and to search for possible effects and associations that can be followed up in a larger study.

Source: ScienceDirect

5 – Effect of tocilizumab in adults hospitalized with moderate-severe COVID-19 pneumonia versus standard care

• Tocilizumab is an interleukin-6 receptor-blocking agent proposed for the treatment of severe COVID-19; however, limited data are available on their efficacy.
• The aim of this study was to assess the effect of tocilizumab on the outcomes of patients with COVID-19 pneumonia by using propensity-score-matching (PSM) analysis.
• The administration of tocilizumab in patients with moderate to severe COVID-19 did not reduce the risk of mortality in our cohort of patients, regardless of the time of administration.

Source: ScienceDirect

6 – Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers

• Randomized clinical trials have provided estimates of the effectiveness of the BNT162b2 vaccine against symptomatic SARS-CoV-2 infection, but its effect on asymptomatic infections remains unclear.
• This study aims to estimate the association between receipt of the Pfizer-BioNTech BNT162b2 vaccine and the incidence of symptomatic and asymptomatic SARS-CoV-2 infection among health care workers.
• Among health care workers, receipt of the BNT162b2 vaccine compared with no vaccine was associated with a significantly lower incidence of symptomatic and asymptomatic SARS-CoV-2 infection more than 7 days after the second dose.

Source: JAMA Network

• Read more from FADIC Blog, with many articles with evidence based articles.
• Learn More Through FADIC® – Online Programs & Mini-Courses.
• Listen Now to FADIC Podcast focusing on varieties of pharmacist perspectives in specialties.
• Read More Now about FADIC Pharmacy Events to get more Experience.

Course Copyrights:

All Courses is meant for SINGLE user use only.
If more than one person acceced this course, they will be BLOCKED Forever.

Why FADIC 2021 Pharmacotherapy Daily News (FNN) ?

• It helps to keep up with the literature!
• Provide you with the Updated with the latest in your clinical practice. Wherever you are, and Whenever you need!
• Help you to share in the advance in clinical career. In addition to adding an impressive image to the pharmacists all-around!

Subscribe to FADIC 2021 Pharmacotherapy Daily News (FNN), for a publication of E-News

Read & Download FNN Issue 8 of April 2020 FNN News